Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients

C. Würnschimmel, M. Wenzel, F. Chierigo, RS. Flammia, Z. Tian, F. Saad, A. Briganti, SF. Shariat, N. Suardi, C. Terrone, M. Gallucci, FK. Chun, D. Tilki, M. Graefen, PI. Karakiewicz

. 2022 ; 29 (1) : 17-24. [pub] 20210922

Jazyk angličtina Země Austrálie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011500

OBJECTIVES: To test the effect of race/ethnicity on cancer-specific mortality after radical prostatectomy or external beam radiotherapy in localized prostate cancer patients. METHODS: In the Surveillance, Epidemiology and End Results database 2004-2016, we identified intermediate-risk and high-risk white (n = 151 632), Asian (n = 11 189), Hispanic/Latino (n = 20 077) and African American (n = 32 550) localized prostate cancer patients, treated with external beam radiotherapy or radical prostatectomy. Race/ethnicity-stratified cancer-specific mortality analyses relied on competing risks regression, after propensity score matching for patient and cancer characteristics. RESULTS: Compared with white patients, Asian intermediate- and high-risk external beam radiotherapy patients showed lower cancer-specific mortality (hazard ratio 0.58 and 0.70, respectively, both P ≤ 0.02). Additionally, Asian high-risk radical prostatectomy patients also showed lower cancer-specific mortality than white patients (hazard ratio 0.72, P = 0.04), but not Asian intermediate-risk radical prostatectomy patients (P = 0.08). Conversely, compared with white patients, African American intermediate-risk radical prostatectomy patients showed higher cancer-specific mortality (hazard ratio 1.36, P = 0.01), but not African American high-risk radical prostatectomy or intermediate- and high-risk external beam radiotherapy patients (all P ≥ 0.2). Finally, compared with white people, no cancer-specific mortality differences were recorded for Hispanic/Latino patients after external beam radiotherapy or radical prostatectomy, in both risk levels (P ≥ 0.2). CONCLUSIONS: Relative to white patients, an important cancer-specific mortality advantage applies to intermediate-risk and high-risk Asian prostate cancer patients treated with external beam radiotherapy, and to high-risk Asian patients treated with radical prostatectomy. These observations should be considered in pretreatment risk stratification and decision-making.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011500
003      
CZ-PrNML
005      
20220506130352.0
007      
ta
008      
220425s2022 at f 000 0|eng||
009      
AR
024    7_
$a 10.1111/iju.14701 $2 doi
035    __
$a (PubMed)34553428
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a at
100    1_
$a Würnschimmel, Christoph $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Quebec, Canada
245    10
$a External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients / $c C. Würnschimmel, M. Wenzel, F. Chierigo, RS. Flammia, Z. Tian, F. Saad, A. Briganti, SF. Shariat, N. Suardi, C. Terrone, M. Gallucci, FK. Chun, D. Tilki, M. Graefen, PI. Karakiewicz
520    9_
$a OBJECTIVES: To test the effect of race/ethnicity on cancer-specific mortality after radical prostatectomy or external beam radiotherapy in localized prostate cancer patients. METHODS: In the Surveillance, Epidemiology and End Results database 2004-2016, we identified intermediate-risk and high-risk white (n = 151 632), Asian (n = 11 189), Hispanic/Latino (n = 20 077) and African American (n = 32 550) localized prostate cancer patients, treated with external beam radiotherapy or radical prostatectomy. Race/ethnicity-stratified cancer-specific mortality analyses relied on competing risks regression, after propensity score matching for patient and cancer characteristics. RESULTS: Compared with white patients, Asian intermediate- and high-risk external beam radiotherapy patients showed lower cancer-specific mortality (hazard ratio 0.58 and 0.70, respectively, both P ≤ 0.02). Additionally, Asian high-risk radical prostatectomy patients also showed lower cancer-specific mortality than white patients (hazard ratio 0.72, P = 0.04), but not Asian intermediate-risk radical prostatectomy patients (P = 0.08). Conversely, compared with white patients, African American intermediate-risk radical prostatectomy patients showed higher cancer-specific mortality (hazard ratio 1.36, P = 0.01), but not African American high-risk radical prostatectomy or intermediate- and high-risk external beam radiotherapy patients (all P ≥ 0.2). Finally, compared with white people, no cancer-specific mortality differences were recorded for Hispanic/Latino patients after external beam radiotherapy or radical prostatectomy, in both risk levels (P ≥ 0.2). CONCLUSIONS: Relative to white patients, an important cancer-specific mortality advantage applies to intermediate-risk and high-risk Asian prostate cancer patients treated with external beam radiotherapy, and to high-risk Asian patients treated with radical prostatectomy. These observations should be considered in pretreatment risk stratification and decision-making.
650    _2
$a černoši nebo Afroameričané $7 D001741
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prostata $7 D011467
650    _2
$a prostatický specifický antigen $7 D017430
650    12
$a prostatektomie $7 D011468
650    12
$a nádory prostaty $x radioterapie $x chirurgie $7 D011471
655    _2
$a časopisecké články $7 D016428
700    1_
$a Wenzel, Mike $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Quebec, Canada $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Chierigo, Francesco $u Department of Urology, Policlinico San Martino Hospital, University of Genova, Genoa, Italy
700    1_
$a Flammia, Rocco Simone $u Department of Maternal-Child and Urological Sciences, Policlinico Umberto I Hospital, Sapienza Rome University, Rome, Italy
700    1_
$a Tian, Zhe $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Quebec, Canada
700    1_
$a Saad, Fred $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Quebec, Canada
700    1_
$a Briganti, Alberto $u Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York City, New York, USA $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
700    1_
$a Suardi, Nazareno $u Department of Urology, Policlinico San Martino Hospital, University of Genova, Genoa, Italy
700    1_
$a Terrone, Carlo $u Department of Urology, Policlinico San Martino Hospital, University of Genova, Genoa, Italy
700    1_
$a Gallucci, Michele $u Department of Maternal-Child and Urological Sciences, Policlinico Umberto I Hospital, Sapienza Rome University, Rome, Italy
700    1_
$a Chun, Felix Kh $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Tilki, Derya $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany $u Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Graefen, Markus $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Quebec, Canada
773    0_
$w MED00007209 $t International journal of urology : official journal of the Japanese Urological Association $x 1442-2042 $g Roč. 29, č. 1 (2022), s. 17-24
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34553428 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130344 $b ABA008
999    __
$a ok $b bmc $g 1789217 $s 1162698
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 29 $c 1 $d 17-24 $e 20210922 $i 1442-2042 $m International journal of urology $n Int J Urol $x MED00007209
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace